Does the UPC serve up new feeding grounds for US non-practising entities?

Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

UPC Court of Appeal revokes NanoString injunction in first substantive decision

27 February 2024 UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing.

Big Pharma

UPC confirms dates for 10x Genomics hearings

22 August 2023 UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.

More features

The Quintara decision: Defining trade secrets in federal cases

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Does the UPC serve up new feeding grounds for US non-practising entities?

More on this story

Editor's picks

Editor's picks

More features